Ocular Therapeutix prices initial public offering at $13 per share

Ocular Therapeutix has priced its initial public offering of 5,000,000 common stock shares at $13 per share, before underwriting discounts and commissions, according to a company press release.The company has also granted the underwriters an option for a 30-day purchase period at the public offering price excluding the underwriting discount — up to 750,000 additional shares of common stock to cover over-allotments, according to the press release.

European authorities recommend marketing extension for Ozurdex

The European Union’s Committee for Medicinal Products for Human Use has recommended extending the marketing authorization for the dexamethasone 700 mcg intravitreal implant in applicator, according to an Allergan press release.Dexamethasone 700 mcg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with vision loss due to diabetic macular edema who are pseudophakic, or who are unable to undergo non-corticosteroid therapy.

BLOG: Managing associate optometrists in your practice, part 3

Hiring a new optometrist — or properly managing the doctors you have — should start with a position description. This should include the following elements:Scope of practiceThe practice’s optometrists will practice to the highest levels permitted by state practice regulations and payer stipulations, and within the boundaries set by the medical director.